DIAGNOSTIC VALUE OF CHROMOSOMAL MICROARRAY ANALYSIS IN PATIENTS WITH CONGENITAL ANOMALIES AND DYSMORPHIC FEATURES; DETAILS OF TWO NEW PATIENTS WITH 2q33 DELETIONS

Year 2024, Volume: 26 Issue: 3, 300 - 307, 24.12.2024

Pelin Özyavuz Çubuk , Ece Keskin , Lamiya Mardan Hacızade , Tuğba Akın Duman , Fatma Nihal Öztürk , Ömer Faruk Karaçorlu , Hasan Taslidere , Mehmet Bugrahan Duz

Abstract

Objective: Detection of copy number variations (CNVs) through molecular karyotyping is a useful method to assess the genetic anomalies with dysmorphic features and multiple congenital anomalies. This study demonstrated the diagnostic rate of chromosomal microarray analysis in patients with specific phenotype, and also contributed the literature with presenting new patients with very rare CNVs.
Material and Methods: Chromosomal microarray analysis was performed in 419 patients with dysmorphic features and multiple congenital anomalies.
Results: A total of 61 CNVs were detected in 50 patients (12%). Two of these patients exhibited a 2q33.1 deletion. While patient 13 presented with speech delay, seizures, behavioral abnormalities, and a 469 kbp deletion disrupting SATB2, patient 14 displayed immune deficiency, failure to thrive, hypothyroidism, diarrhea, cryptorchidism, and ectodermal features such as alopecia, nail dysplasia, and oligodontia. This patient had a 7.5 Mb deletion on 2q33.1q34, which included CTLA4 and was responsible for the immune deficiency symptoms of the patient. The CASP10, was not included in the deletion region.
Conclusions: According to our study, co-deletion of CTLA4 and CASP10 did not lead to phenotypic effects like immune deficiency. Rather, only the deletion of the CTLA4 gene may result in hypogammaglobulinemia and immune deficiency. These findings suggest that chromosomal microarray analysis can be a valuable tool in diagnosing rare CNVs and guiding clinical management, particularly in patients with immune deficiency and other congenital anomalies. Identifying specific gene deletions, such as CTLA4, may inform personalized treatment approaches, including immune-modulating therapies, and provide insights for genetic counseling in affected families.

Keywords

Congenital anomaly, dysmorphic features, molecular karyotyping, 2q33.1 deletion, chromosomal microarray

Konjenital Anomalisi ve Dismorfik Özellikleri olan Hastalarda Kromozomal Mikroarray Analizinin Tanısal Değeri; 2q33 delesyonu olan İki Yeni Hastanın Ayrıntıları

Abstract

Amaç: Moleküler karyotipleme yoluyla kopya sayısı varyasyonlarının (CNV'ler) tespiti, dismorfik özellikler ve birden fazla konjenital anomali (MCA) ile ilişkili genetik anomalileri ortaya çıkarmak için kullanışlıdır. Bu çalışma, belirli fenotipe sahip hastalarda kromozomal mikrodizin analizinin tanısal oranını göstermekte ve çok nadir CNV'lere sahip yeni hastaları sunarak literatüre katkıda bulunmaktadır.
Gereç ve Yöntemler: Dismorfik özellikler ve birden fazla konjenital anomaliye sahip 419 hastada kromozomal mikrodizin analizi gerçekleştirildi.
Bulgular: Toplamda 50 hastada (%12) 61 CNV tespit edildi. Bu hastalardan ikisinde 2q33.1 delesyonu saptandı. Hasta 13 konuşma gecikmesi, nöbetler, davranış bozuklukları ve SATB2 genini bozan 469 kbp delesyon ile kendini gösterirken; hasta 14, immün yetmezlik, büyüme geriliği, hipotiroidizm, ishal, inmemiş testisler ve alopesi, tırnak displazisi ve oligodonti gibi ektodermal özellikler sergiledi. Bu hastada, 2q33.1q34 bölgesinde CTLA4 genini içeren ve immün yetmezlik belirtilerine neden olan 7.5 Mb delesyon mevcuttu. CASP10 geni ise delesyon bölgesinde yer almamaktadır.
Sonuç: Çalışmamıza göre, CTLA4 ve CASP10 genlerinin birlikte delesyonu bağışıklık yetmezliği gibi fenotipik etkilere yol açmaz iken, yalnızca CTLA4 geninin delesyonu hipogamaglobulinemi ve bağışıklık yetmezliği ile sonuçlanabilir. Bu bulgular, moleküler karyotiplemenin nadir CNV'lerin tanısında ve doğumsal anomalileri olan hastaların klinik yönetiminde değerli bir araç olabileceğini göstermektedir. CTLA4 gibi spesifik gen delesyonlarının belirlenmesi, bağışıklık düzenleyici tedaviler de dahil olmak üzere kişiselleştirilmiş tedavi yaklaşımlarına kapı açabilir ve etkilenen ailelerde genetik danışmanlık için önemli bilgiler sağlayabilir.

Keywords

Konjenital anomali, dismorfik bulgular, moleküler karyotipleme, 2q33.1 delesyonu, kromozomal mikrodizin

References

• Sagoo GS, Butterworth AS, Sanderson S, Shaw-Smith C, Higgins JP, Burton H. Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genet Med. 2009;11(3):139-146.
• Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749-764.
• Hochstenbach R, van Binsbergen E, Engelen J, et al. Array analysis and karyotyping: workflow consequences based on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands. Eur J Med Genet. 2009;52(4):161–169.
• Gerik-Celebi HB, Aydin H, Bolat H, Unsel-Bolat G. Clinical and Genetic Characteristics of Patients with Unexplained Intellectual Disability/Developmental Delay without Epilepsy. Mol Syndromol. 2023;14(3):208-218
• Ceylan AC, Citli S, Erdem HB, Sahin I, Acar Arslan E, Erdogan M. Importance and usage of chromosomal microarray analysis in diagnosing intellectual disability, global developmental delay, and autism; and discovering new loci for these disorders. Mol Cytogenet. 2018;11:54.
• Unal AT, Durmaz CD. Konjenital Anomali ve/veya Nörogelişimsel Geriliği olan Çocukluk Çağındaki Türk Hastalarda Kromozomal Mikroarray Deneyimi: ASXL2 Gen Duplikasyonu ve Xq13 Delesyonunun İncelenmesi. Dicle Tıp Dergisi, 2024;50(1):135-148.
• Çebi AH, Altıner Ş. Application of Chromosome Microarray Analysis in the Investigation of Developmental Disabilities and Congenital Anomalies: Single Center Experience and Review of NRXN3 and NEDD4L Deletions. Mol Syndromol. 2020;11(4):197-206.
• Utine GE, Haliloglu G, Volkan-Salanci B, et al. Etiological yield of SNP microarrays in idiopathic intellectual disability. Eur J Paediatr Neurol. 2014;18:327–337.
• Arican P, Olgac Dundar N, Ozyilmaz B, et al. Chromosomal Microarray Analysis in Children with Unexplained Developmental Delay/Intellectual Disability. J Pediatr Genet. 2019;8(1):1-9.
• Ayaz A, Gezdirici A, Yilmaz Gulec E, et al. Diagnostic Value of Microarray Method in Autism Spectrum Disorder, Intellectual Disability, and Multiple Congenital Anomalies and Some Candidate Genes for Autism: Experience of Two Centers. Medeni Med J. 2022;23;37(2):180-193.
• Ozyilmaz B, Kirbiyik O, Koc A, et al. Experiences in microarray-based evaluation of developmental disabilities and congenital anomalies. Clin Genet. 2017;92(4):372-379.
• Sagoo GS, Butterworth AS, Sanderson S, Shaw-Smith C, Higgins JP, Burton H. Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genet Med. 2009;11:139–146.
• Daghsni M, Lahbib S, Fradj M, et al. TOP3B: A Novel Candidate Gene in Juvenile Myoclonic Epilepsy? Cytogenet Genome Res. 2018;154(1):1-5.
• Riley JD, Delahunty C, Alsadah A, Mazzola S, Astbury C. Further evidence of GABRA4 and TOP3B as autism susceptibility genes. Eur J Med Genet. 2020;63(5):103876.
• Kaufman CS, Genovese A, Butler MG. Deletion of TOP3B Is Associated with Cognitive Impairment and Facial Dysmorphism. Cytogenet Genome Res. 2016;150(2):106-111.
• Zhang T, Wallis M, Petrovic V, Challis J, Kalitsis P, Hudson DF. Loss of TOP3B leads to increased R-loop formation and genome instability. Open Biol. 2019;9(12):190222.
• Balasubramanian M, Smith K, Basel-Vanagaite L, et al. 2011. Case series: 2q33.1 microdeletion syndrome-further delineation of the phenotype. J Med Genet 48:290–298.
• Zarate YA, Fish JL. SATB2-associated syndrome: Mechanisms, phenotype, and practical recommendations. Am J Med Genet A. 2017;173(2):327-337.
• Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):14106.
• Zeissig S, Petersen BS, Tomczak M, et al. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. Gut. 2015; 64(12):188997.
• Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623-1627.
• Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018;142(6):1932-1946.
• Wang J, Zheng L, Lobito A, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98(1):47-58.